Results from AIRFLOW-2 Trial Reveal Reduction in Exacerbations and other Respiratory Adverse Events PARIS, Sept. 18, 2018 – Nuvaira, a developer of medical devices to treat obstructive lung diseases, announced the acceptance of a clinical abstract by the European Respiratory Society (ERS) for oral presentation at the 28th International Congress 2018 in Paris. Co-principal Investigator, Dirk-Jan Slebos, M.D., Ph.D., from the University Medical Center Groningen in the Netherlands, today will make the first public presentation of results from the AIRFLOW-2 clinical trial (NCT#02058459), the first multi-center, double-blind, randomized, sham-controlled study of Targeted Lung Denervation (TLD) using the Nuvaira™ Lung Denervation […]
3750 Annapolis Lane North
Minneapolis, MN 55447
© 2018 Nuvaira Inc. All rights reserved.